Infinity Pharmaceuticals, Inc. (INFI)

I'm back to try and cement my immortality with Infinity. My gestalt feeling about the stock is that the floor is in at 5.5 at least for the short-term. I don't think I'm going to be taking one of those infamous biotech 50% haircuts on a stub with 150M cash and 113M shareholder equity, and a market cap of 154M. I'm not a fan of the pipeline long term as their lead candidate retaspimycin wasn't exactly stellar in the only phase III trial so far (terminated early after higher mortality rate in study arm). But in July the share price rapidly rose 75% for no apparent reason (except possibly their addition to the Russell 2000) before drifting back to present levels. A buyout remains a real possibility (remember Kosan!). But I wouldn't buy this stub in real unless it dropped below shareholder equity, which is only likely to happen on an overreaction to another retaspimycin trial termination.

outperform. company is HIGH in cash. not terribly overvalued, and is likely to kill S&P 500 where it is at today's levels.
additionally these companies are not within the financials nor energy sectors.